Via pharma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 447,961 | 412,735 | 298,070 | 258,733 | 114,039 | 49,866 | 75,983 | 236,537 |
| Profit before tax | 27,629 | 22,012 | 23,850 | 32,764 | 10,310 | -19,824 | -51,473 | -9,192 |
| Net profit | 23,860 | 18,603 | 19,918 | 27,849 | 8,763 | -19,824 | -51,473 | -9,192 |
| Equity | 30,030 | 48,633 | 68,551 | 96,400 | 95,163 | 75,338 | 23,865 | 14,674 |
| Liabilities | 407,017 | 192,496 | 146,041 | 83,995 | 79,973 | 60,661 | 62,021 | 194,696 |
| Non-current assets | 621 | 1,333 | 1,467 | 721 | 221 | 1 | 1 | 1 |
| Current assets | 436,426 | 239,796 | 213,125 | 179,674 | 174,915 | 135,998 | 85,885 | 209,369 |
| Total assets | 437,047 | 241,129 | 214,592 | 180,395 | 175,136 | 135,999 | 85,886 | 209,370 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 5,986 | 3,278 | 1,241 |
| Social insurance contributions | - | - | - | - | - | 1,152 | 3,452 | 3,448 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -20.4% | -7.9% | -27.8% | -13.2% | -55.9% | -56.3% | +52.4% | +211.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 5.5% | 7.7% | 9.3% | 15.4% | 5.0% | -14.6% | -59.9% | -4.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 79.5% | 38.3% | 29.1% | 28.9% | 9.2% | -26.3% | -215.7% | -62.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 5.3% | 4.5% | 6.7% | 10.8% | 7.7% | -39.8% | -67.7% | -3.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 6.2% | 5.3% | 8.0% | 12.7% | 9.0% | -39.8% | -67.7% | -3.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 13.6 | 4.0 | 2.1 | 0.9 | 0.8 | 0.8 | 2.6 | 13.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 149,320 | 137,578 | 99,357 | 86,244 | 38,013 | 14,960 | 18,996 | 59,134 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Via pharma - Social security debts
The company had no debts to Sodra
Via pharma - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Via pharma, UAB (code 302481966) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated €236.5K in revenue, up 211.3% year on year and 374.4% over two years, showing a strong sales expansion from €49.9K in 2023 and €76.0K in 2024. Despite the higher turnover, the business remained loss-making, with net profit of -€9.2K in 2025, an improvement from -€51.5K in 2024 and -€19.8K in 2023. The 2025 profit margin was -3.9%, indicating that losses narrowed materially as revenue increased. At year-end 2025, total assets stood at €209.4K, equity at €14.7K, and liabilities at €194.7K. The equity ratio was 7.0% and debt-to-equity was 13.27, reflecting a highly leveraged balance sheet. Asset turnover was 1.13x. With one employee, revenue per employee reached €59.1K, while profit per employee was -€2.3K.